<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116740</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-004</org_study_id>
    <nct_id>NCT00116740</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of APD356 in the Treatment of Obesity</brief_title>
  <official_title>A 12-Week, Dose-Ranging, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of APD356 in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c
      receptor agonist, in clinical development as a potential treatment for obesity.

      The purpose of this study is to obtain a preliminary assessment of the safety and efficacy of
      APD356, when administered daily for 12 weeks, in obese subjects who are otherwise healthy.
      Subjects who are on concomitant medications for control of hypertension or blood lipids may
      qualify.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, parallel group study. Three different
      doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and
      nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects
      will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in waist circumference, hip circumference, and waist/hip ratio</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD356</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or nonpregnant, nonlactating females aged 18-65 years (inclusive)

          -  Body mass index (BMI) of 30-45 kg/m2

          -  Non-smoker

          -  No concomitant medications other than hypertension medications (stable &gt; 90 days)
             and/or statins (stable &gt; 90 days)

          -  No past treatment with drugs associated with the development of pulmonary hypertension
             or cardiac valvular insufficiency

          -  No more than mild mitral valve regurgitation and absence of aortic valve regurgitation
             upon screening echocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William R Shanahan, Jr., MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.obesityonline.org/</url>
    <description>obesity information</description>
  </link>
  <link>
    <url>http://www.obesity.org/</url>
    <description>N. American Association for the Study of Obesity web page</description>
  </link>
  <link>
    <url>http://www.arenapharm.com</url>
    <description>sponsor company web page</description>
  </link>
  <link>
    <url>http://www.pbrc.edu</url>
    <description>Pennington Biomedical Research Center home web page</description>
  </link>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2005</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <keyword>Serotonin</keyword>
  <keyword>5-HT2c</keyword>
  <keyword>Satiety</keyword>
  <keyword>Obesity</keyword>
  <keyword>Appetite suppressant</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

